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The high-risk patient has been haunting us for years. Before
the endovascular era, very few patients were actually denied open
aneurysm repair on account of extensive cardiovascular comorbid-
ity and the increased mortality this type of surgery would be
associated with. With the advent of endovascular aneurysm repair
(EVAR), things changed. Because this therapy was initially consid-
ered most appropriate for patients who had a prohibitive risk for
open surgery, an epidemic of high-risk patients seemed to ensue.
In the subsequent years, many efforts were made to define “high
risk,” but a widely accepted definition could not be accomplished.
Recently, the EVAR-2 trial generated renewed interest in the
preoperative risk profile of abdominal aortic aneurysm (AAA)
patients, as it concluded that EVAR offers no benefit for high-risk
patients compared with best medical treatment. Unfortunately, the
EVAR-2 trialists had also failed to agree upon a clear definition of
their high-risk patients.
The Glasgow Aneurysm Scale (GAS) is a simple score that can
be calculated in the office without complex formulas. It provides a
numerical score representing the preoperative risk profile of an
AAA patient. In a retrospective study, Hirzalla et al aimed at an
external validation of the GAS score as a predictor for postoperative
mortality and major morbidity after elective open AAA repair.
They conclude that the GAS is a valid predictor for postoperative
mortality and morbidity, but that it should merely be used to
identify low-risk patients and not to identify high-risk patients.
Apart from this being a bit of a disappointment in itself (we are
really after a score that defines high-risk), a few methodologic
issues of this study and some other limitations of the GAS score
need to be highlighted.
The study population that was used to validate the GAS score
consisted of patients who were all considered suitable for open
repair between 1994 and 2003. It is very likely that in the same
period, patients who were considered at high risk for open repair
(by whatever criteria) were treated by EVAR in this institution. As
a result, young, low-risk patients are probably over-represented in
the current study population.
Unfortunately, the authors also included juxtarenal and supra-
renal AAA repairs. As this subgroup is responsible for three of the
total five deaths, it obviously plays a major role in the study
outcome. With only two deaths in the remaining 193 infrarenal
AAA repairs, one thing is clear for these authors: they really do not
need a scoring system to predict deaths, as their mortality rate of
open AAA-repair is exceptionally good. The reader is left with the
conclusion that GAS may be helpful in identifying low-risk patients
for this infrarenal AAA population, while this seems to be based
upon a study population void of high-risk patients.
Furthermore, it is important to realize that age is a major
driver of the GAS score. The typical median of AAA patients at the
time of surgery is between 70 and 75, which means that almost half
of all AAA patients considered for repair already fall into the
high-risk GAS-category (77 points) on account of their age
alone. With a history cerebrovascular or renal disease, it becomes
almost impossible for a patient to qualify as low risk. Fortunately,
these risk factors are uncommon (13% and 6%, respectively, in the
current study). Patients with myocardial disease can only qualify as
low risk if they are in their 60s. It therefore must be questioned if
GAS really offers a lot more predictive power than age alone. Not
to mention the issue of corrected or improved cardiac disease not
being accounted for in the GAS score, as appropriately addressed
by the authors.
In conclusion, the authors are to be commended for tackling a
vital issue in current AAA practice. The GAS score is a clever and
simple test that deserves further evaluation; however, it needs
application in larger studies with a higher proportion of patients
with significant risk factors.
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